Otoprotective and antioxidant activity of cytoflavin in pulmonary tuberculosis patients receiving amikacin

Abstract

The objective: to study the potential otoprotective and antioxidant activity of cytoflavin in new pulmonary tuberculosis patients receiving aminoglycoside amikacin.Subjects and Methods. A randomized controlled trial was conducted and included 90 patients with new infiltrative pulmonary tuberculosis with decay, of both genders aged from 20 to 50 years old. Clinical, paraclinical and statistical methods were used in the study. Audiometric screening was carried out by Diagnostic Audiometer AD 226. The degree of antioxidant protection was determined by the oxidation reaction of ABTS in blood serum and plasma.Results. The study included 4 groups of tuberculosis patients and 1 group of healthy donors. Dissemination of pulmonary tuberculosis in 4 groups was approximately the same and was measured by scores. Prior to the start of treatment in all 4 groups (the group receiving standard chemotherapy (CTX) without amikacin, the group receiving «CTX+amikacin», the group receiving «CTX+cytofl avin», the group receiving «CTX+amikacin+cytofl avin») there was a decrease in blood antioxidant activity compared to Control Group. After 3 months of tuberculosis treatment in all 4 groups, the results improved, while in «CTX+Cytofl avin» Group they were similar to Control Group, and «CTX+Amikacin+Cytofl avin Group», they were only 4.8% less. The elevated level of leukocytes decreased by 10.6% in CTX Group, 16.9% in «CTX+Amikacin» Group, 38.3% in «CTX+Cytofl avin» Group, and 72.3% in «CTX+Amikacin+Cytofl avin» Group. In the study, manifestations of oto- and vestibulotoxicity were found only in the «CTX+Amikacin» Group (in 4/20 (5%)). There were no such cases in «Amikacin+Cytofl avin» Group consisting of 23 patients.